We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
198 hedge funds and large institutions have $11.4B invested in Royalty Pharma in 2020 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 70 increasing their positions, 24 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
244% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 27
192% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 24
74% more capital invested
Capital invested by funds: $6.52B → $11.4B (+$4.84B)
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
48% more funds holding
Funds holding: 134 → 198 (+64)
15.77% more ownership
Funds ownership: 43.53% → 59.3% (+16%)
54% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $39.4M
Holders
198
Holders Change
+64
Holders Change %
+47.76%
% of All Funds
3.5%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.18%
New
93
Increased
70
Reduced
24
Closed
27
Calls
$18.1M
Puts
$39.4M
Net Calls
-$21.3M
Net Calls Change
-$20.1M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$612M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$287M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$258M |
| 4 |
BlackRock
New York
|
+$226M |
| 5 |
CCM
CAAS Capital Management
New York
|
+$153M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$310M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$213M |
| 3 |
BL
Bleichroeder LP
New York
|
-$38.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$26.4M |
| 5 |
Blackstone Inc
New York
|
-$15.3M |
